Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
AIMS: This study assessed the cost-effectiveness of the subcutaneous RANKL inhibitor, denosumab, vs the intravenous bisphosphonate, zoledronic acid, for the prevention of skeletal-related events (SREs) in patients with prostate cancer, breast cancer, and other solid tumors (OST) in the Czech Republic. MATERIALS AND METHODS: A lifetime Markov model was developed to compare the effects of denosumab and zoledronic acid on costs (including drug costs and administration, patient management, SREs, and adverse events), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios from a national payer perspective. Different discount rates, time horizons, SRE rates, distributions, and nature (asymptomatic vs all SREs), and the inclusion of treatment discontinuation were considered in scenario analyses. The robustness of the model was tested using deterministic and probabilistic sensitivity analyses. RESULTS: Across tumor types, denosumab was associated with fewer SREs, improved QALYs, and higher total costs over a lifetime. The incremental cost per QALY gained for denosumab vs zoledronic acid was 382,673 CZK for prostate cancer, 408,450 CZK for breast cancer, and 608,133 CZK for OST. Incremental costs per SRE avoided for the same tumor type were 54,007 CZK, 51,765 CZK, and 94,426 CZK, respectively. In scenario analyses, the results remained similar to baseline, when different discount rates and time horizons were considered. At a non-official willingness-to-pay threshold of 1.2 million CZK, the probabilities of denosumab being cost-effective vs zoledronic acid were 0.64, 0.67, and 0.49 for prostate cancer, breast cancer, and OST, respectively. LIMITATIONS: The SRE rates used were obtained from clinical trials; studies suggest rates may be higher in clinical practice. Additional evidence on real-world SRE rates could further improve the accuracy of the modeling. CONCLUSIONS: Compared with zoledronic acid, denosumab provides a cost-effective treatment option for the prevention of SREs in patients with prostate cancer, breast cancer, and OST in the Czech Republic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the publications regarding trastuzumab and rituximab, eight other publications were identified that report relative time or cost information for IV versus SC administration (Table 2) [112–119]”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“Almost all patients with prostate cancer, the majority of patients with breast cancer, and a large proportion of patients with lung or kidney cancer will develop bone metastases during the advanced stages of their disease [1,2].”
Decision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920 · cited 2×
“Almost all patients with prostate cancer, the majority of patients with breast cancer, and a large proportion of patients with lung or kidney cancer will develop bone metastases during the advanced stages of their disease [1,2].”
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597 · cited 1×
“SRE type distribution (pooled across both treatment groups)[13-15] Pathologic fracture 0.”
Effectiveness of strategies for informing, educating, and involving patients
Coulter, A., & Ellins, J. (2007) · BMJ · doi:10.1136/bmj.39246.581169.80 · Cited by 1,128 · cited 1×
“Engaging patients in treatment decision making is important and can lead to improved outcomes [47]; therefore patient preference may be an additional valuable parameter that could be included in cost-effective analysis models such as those presented here.”
Cronin, K. A., Ries, L. A. G., & Edwards, B. K. (2014) · Cancer · doi:10.1002/cncr.29049 · Cited by 699
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.014 · Cited by 588 · cited 1×
“The analysis considers a lifetime horizon [22]; the model was run for 200 cycles (approximately 15.”
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588 · cited 2×
“As reported by Lipton et al.16, denosumab showed a clinical benefit across patients with advanced solid tumors and bone metastases in comparison with zoledronic acid, including in patients with a prior history of SREs.”
Research works printed but not linked: 2
- Barton GR, 2008, Health, 11, 886
- International Agency for Research on Cancer, WHO. Chapter 2: Rates and rate standardization. In: N.E. Breslow and N.E. Day Eds Statistical methods in cancer research volume II: the design and analysis of cohort studies. Lyon, France: Oxford University Press; 1987, pp 48-81
Cited by
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
von Moos, R., Costa, L., González‐Suárez, E., Terpos, E., Niepel, D., & Body, J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.003 · Cited by 151
“While the acquisition cost of the monoclonal antibody denosumab is higher than that of generic bisphosphonates, cost-effectiveness analysis has shown that incremental costs per quality-adjusted life year (QALY) and per SRE avoided with denosumab are well below willingness-to-pay thresholds, and thus denosumab can be c…”
BackgroundMcCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
“IVadministered zoledronic acid) rather than treatment with a targeted oncology drug [112, 114, 115].”
BackgroundStopeck, A., Brufsky, A., Kennedy, L., Bhatta, S., Bhowmik, D., Buchanan, J., Despiégel, N., & Hechmati, G. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1651122 · Cited by 32
Terpos, E., Jamotte, A., Christodoulopoulou, A., Campioni, M., Bhowmik, D., Kennedy, L., & Willenbacher, W. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1606002 · Cited by 20
Wajda, B. G., Ferrie, L., Abbott, A. G., Assadzadeh, G. E., Monument, M. J., & Kendal, J. K. (2025) · Cancers · doi:10.3390/cancers17030388 · Cited by 22
“…is needed to deepen our understanding of pain management and HRQoL, and to address methodological variances in cost-effectiveness analyses to refine our understanding of these agents’ economic value and optimize decision-making for MBD management, considering both clinical and economic factors.”
Influential
Metadata
- Authors
- Cristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M.
- Affiliations
- Amgen (Switzerland) (CH)
- Pilsen Faculty Hospital, Clinic of Oncology and Radiotherapy (FN v Plzni), Pilsen, Czech Republic;
- Amgen s.r.o., Prague, Czech Republic;
- Oaks Consulting, Prague, Czech Republic;
- Amgen (United States) (US)
- Amgen (Europe) GmbH, Zug, Switzerland;
- Venue
- Journal of Medical Economics
- Publisher
- Informa UK Limited
- Published
- 2017-06-07
- Volume
- 20
- Issue
- 8
- Pages
- 799-812
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W2613642134
- Cited by
- 16
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 1
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Medical Economics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- denosumab, zoledronic acid, cost-effectiveness, skeletal-related events, RANKL inhibitor, bisphosphonates, prostate cancer, breast cancer, solid tumors, quality-adjusted life years, incremental cost-effectiveness ratio, Czech Republic
- MeSH terms
- Denosumab, Zoledronic Acid, Bone Diseases, Breast Neoplasms, Cost-Benefit Analysis, Diphosphonates, Double-Blind Method, Female, Humans, Imidazoles, Male, Markov Chains, Neoplasms, Prostatic Neoplasms, Quality of Life, Models, Econometric, Czech Republic, Quality-Adjusted Life Years, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. https://app.cochat.ai/papers/10.1080/13696998.2017.1328423
- The paper
- Cristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M. (2017). Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. Journal of Medical Economics. https://doi.org/10.1080/13696998.2017.1328423
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.